MAZ51

产品编号: DC11285 Featured
MAZ51
结构式
163655-37-6
此产品仅供科研所需,我们不出售给病人
​我们将匹配市场上最好的价格给您
Email:order@dcbio.cn
免费咨询电话:4008862077
我们的合作伙伴:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
中国地区超过5000个高品质化合物库存
应用领域
MAZ51 是 VEGFR-3 酪氨酸激酶的选择性抑制剂。MAZ51 抑制 VEGF-C 诱导的 VEGFR-3 激活,而没有阻断 VEGF-C 介导的VEGFR2 刺激。MAZ51 对配体诱导的 EGFR,IGF-1R 和 PDGFRβ 的自磷酸化没有影响。MAZ51 阻止增殖并诱导多种肿瘤细胞凋亡。具有抗肿瘤活性。
Cas No.: 163655-37-6
名称: 3-[[4-(dimethylamino)-1-naphthalenyl]methylene]-1,3-dihydro-2H-indol-2-one
别名: MAZ51,MAZ-51,MAZ 51
SMILES: CN(C)C1=C(C=CC=C2)C2=C(/C=C3C(NC4=C/3C=CC=C4)=O)C=C1
分子式: C21H18N2O
分子量: 314.4
纯度:
保存条件: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description:
In Vivo:
In Vitro:
References: MAZ51 is an indolinone that selectively antagonizes the activation of VEGFR3 by VEGFC (IC50 = 1 µM) without blocking VEGFC-mediated stimulation of VEGFR2.It does not inhibit ligand-induced autophosphorylation of EGFR, IGF-1R, or PDGFRβ.By preventing VEGFR3 activation, MAZ51 interferes with an autocrine loop involving the induced expression of the ligand VEGFC as well as VEGFA. It reduces proliferation and induces apoptosis in a variety of cancer cells in vitro and suppresses tumor growth in vivo. MAZ51 is used to study the role of VEGFR3 in endothelial and cancer cell function and survival.
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
产品编号 产品名称 应用领域
DCAPI1524 Axitinib Axitinib是多靶点的酪氨酸激酶抑制剂,抑制 VEGFR1,VEGFR2,VEGFR3, PDGFRβ 的 IC50 值分别为4,20,4,2 nM。
DC9781 SU4312(NSC86429) SU4312(NSC86429) is a selective, cell-permeable inhibitor of VEGFR2 and PDGFR tyrosine kinases (IC50s = 0.8 and 19.4 μM, respectively).
DC9680 NVP-BAW2881 NVP-BAW2881 (BAW2881) 是有效,选择性的 VEGFR2 抑制剂,IC50 为值9 nM。
DC8794 NVP-ACC-789 NVP-ACC789 是 人 VEGFR-1,VEGFR-2 (鼠 VEGFR-2),VEGFR-3 和 PDGFR-β 的抑制剂,IC50 值分别为 0.38,0.02 (0.23),0.18 和 1.4 μM。
DC8530 SAR131675 SAR131675是有效,选择性的 VEGFR3 抑制剂,IC50 值为23 nM。
DC8488 LENVATINIB MESYLATE Lenvatinib mesylate (E7080 mesylate),一种口服,多靶点酪氨酸激酶抑制剂,抑制血管内皮生长因子受体 (VEGFR1-3),成纤维细胞生长因子受体 (FGFR1-4),血小板衍生生长因子受体 (PDGFR),干细胞因子受体 (KIT),转染期间重排 (RET),显示有效抗癌的活性。
DC8072 Altiratinib(DCC-2701) Altiratinib (DCC-2701) 是多靶点激酶抑制剂,抑制 MET,TIE2,VEGFR2,FLT3,Trk1,Trk2 和 Trk3 的 IC50 值分别为2.7,8,9.2,9.3,0.85,4.6,0.83 nM。
DC7509 SU1498 SU1498是选择性的VEGFR2抑制剂;抑制Flk-1的IC50值为700 nM。
DC7502 SKLB610 SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR at rate of 97%, 65% and 55%, respectively, at concentration of 10 μM in biochemical kinase assays.
DC7440 KI8751 Ki8751是有效地 VEGFR2 抑制剂,IC50 值为0.9 nM。